Researchers are currently experimenting in laboratories on the bioavailability of oral-buccal administration of peptide to the subcutaneous route, and results so far show that 1mg of peptide sublingually administered daily is equivalent to 5mg weekly subcutaneously. The research aims to suggest alternative methods for alleviating redness, pain, swelling, and total body chills, as well as muscular pain, triggered by subcutaneous administration in approximately 20% of the population. 

The sublingual peptide lozenges come in various forms, shapes, and sizes, ranging from mini capsules to tabs, each enhanced with 3mg Sodium salcaprozate (SNAC) to improve absorption. Sublingual administration was said to be comparable to subcutaneous administration as both do not undergo enzymatic degradation by the gastric acid, and we are offering these for research purposes only.